* Avalo Therapeutics Inc AVTX.OQ AVTX.O is expected
to show a
fall in quarterly revenue when it reports results on August 12
(estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Avalo Therapeutics Inc
is for
a loss of $6.70 per share.
* The one available analyst rating on the shares is
"hold".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $35.00, above its last closing price
of $11.47.
This summary was machine generated August 9 at 18:31 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)